ORTHO 7/7/7 TABLETS (28 DAY) 0.75 MG
NORETHINDRONE : 0.75 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORETHINDRONE : 1 MG NORETHINDRONE : 0.5 MG · DIN 00602965 · JANSSEN INC
Health Canada status: CANCELLED POST MARKET
What is ORTHO 7/7/7 TABLETS (28 DAY)?
ORTHO 7/7/7 TABLETS (28 DAY) 0.75 MG contains NORETHINDRONE : 0.75 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORETHINDRONE : 1 MG NORETHINDRONE : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 00602965, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 01-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ORTHO 7/7/7 TABLETS (28 DAY) used for?
Conception control.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00602965 |
|---|---|
| Brand name | ORTHO 7/7/7 TABLETS (28 DAY) |
| Generic / active ingredient | NORETHINDRONE : 0.75 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORETHINDRONE : 1 MG NORETHINDRONE : 0.5 MG |
| Manufacturer | JANSSEN INC |
| Strength | 0.75 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03AB04 NORETHISTERONE AND ESTROGEN |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Sep-2017 |
| Original market date | 1983-12-31 00:00:00 |
How is it administered?
Oral administration. Usually 21 days of active tablets followed by a 7-day tablet-free interval. Start no earlier than 4 weeks postpartum if not breastfeeding.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists section but text cuts off). Typical storage is 15-30°C.
How is it supplied?
Not explicitly detailed in provided text beyond "Tablets" and "container".
Contraindications
Thrombophlebitis, VTE, cerebrovascular disorders, CAD, liver disease/tumours, breast cancer, undiagnosed vaginal bleeding, pregnancy, migraine with aura, smoking over age 35, severe hypertension.
Warnings and precautions
Cigarette smoking increases risk of serious cardiovascular events, especially in women over 35. Does not protect against STIs/HIV. Risk of VTE, stroke, and hepatic neoplasia.
What can be used instead?
Other Canadian products sharing ATC code G03AB04 NORETHISTERONE AND ESTROGEN. 3 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LOLO | 1 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02417456 |
| SYNPHASIC 21 TABLETS | 0.5 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02187108 |
| SYNPHASIC 28 TABLETS | 1.0 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02187116 |
| ORTHO 10/11 TABLETS (21 DAY) | .035 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | DIN 00538590 |
| ORTHO 10/11 TABLETS (28 DAY) | .5 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | DIN 00538582 |
| ORTHO 7/7/7 TABLETS (21 DAY) | 1 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | DIN 00602957 |
| SYNPHASIC 21 TABLETS | .035 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00620947 |
| SYNPHASIC-28 TABLETS | 1 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00695734 |
Who else supplies NORETHISTERONE AND ESTROGEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NORETHISTERONE AND ESTROGEN appears in 14 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.